Recurrent cardiovascular events with paclitaxel-eluting versus bare-metal stents in saphenous vein graft lesions: insights from the SOS (Stenting of Saphenous Vein Grafts) trial
Tesfaldet T Michael, Abdul-rahman R Abdel-karim, Aristotelis Papayannis, Christopher Lichtenwalter, James A de Lemos, Owen Obel, Tayo Addo, Michele Roesle, Donald Haagen, Bavana V Rangan, Bilal Saeed, Joseph K Bissett, Rajesh Sachdeva, Vassilios V Voudris, Panagiotis Karyofillis, Biswajit Kar, James Rossen, Panayotis Fasseas, Peter B Berger, Subhash Banerjee, Emmanouil S Brilakis, Tesfaldet T Michael, Abdul-rahman R Abdel-karim, Aristotelis Papayannis, Christopher Lichtenwalter, James A de Lemos, Owen Obel, Tayo Addo, Michele Roesle, Donald Haagen, Bavana V Rangan, Bilal Saeed, Joseph K Bissett, Rajesh Sachdeva, Vassilios V Voudris, Panagiotis Karyofillis, Biswajit Kar, James Rossen, Panayotis Fasseas, Peter B Berger, Subhash Banerjee, Emmanouil S Brilakis
Abstract
The Stenting of Saphenous Vein Grafts (SOS) trial demonstrated a reduction in clinical and angiographic adverse events with paclitaxel-eluting stents (PES) compared to bare-metal stents (BMS) in saphenous vein graft (SVG) lesions, but the rate of recurrent adverse events has not been described.
Methods: We performed a post hoc, landmark analysis to evaluate the risk of event recurrence following a non-fatal initial event among the SOS trial patients (pts).
Results: During a median follow-up of 35 months, the 80 pts enrolled in SOS experienced a total of 78 major cardiovascular events (MACE): 51 in the BMS group and 27 in PES group. No MACE were found in 28 pts (35%) while 52 pts (65%) had at least one event. The initial event was death in 13 pts (16%). Among the 39 pts whose initial event was not fatal, 12 (31%) had one or more subsequent MACE (50% of which were definitely related to the study SVG). The mean and median number of MACE per patient was significantly higher in patients receiving BMS versus PES (1.3 ± 1.2 and 1 ± 1.26 versus 0.6 ± 0.7 and 1 ± 0.825, p = 0.005 and p = 0.008, respectively). The rate of a second MACE following an initial event was 17% in the PES group and 37% in the BMS group (p = 0.24). Ten of 12 pts with recurrent events had received a BMS (83%).
Conclusion: Pts undergoing SVG stenting had a high rate of recurrent events after an initial non-fatal event. These events were often related to the target vessel and most occurred in pts who had received a BMS, further supporting the benefit of PES over BMS in SVG lesions.
Source: PubMed